Cargando…

Does treatment strategy influence the ability to achieve and sustain DMARD-free remission in patients with RA? Results of an observational study comparing an intensified DAS-steered treatment strategy with treat to target in routine care

OBJECTIVES: To study the impact of treatment strategy on achieving and sustaining disease-modifying antirheumatic drug (DMARD)-free remission in patients with rheumatoid arthritis (RA). METHODS: Two hundred seventy-nine RA patients (median follow-up 7.8 years) were studied. Of these, 155 patients pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Burgers, L. E., van der Pol, J. A., Huizinga, T. W. J., Allaart, C. F., van der Helm-van Mil, A. H. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6505077/
https://www.ncbi.nlm.nih.gov/pubmed/31064384
http://dx.doi.org/10.1186/s13075-019-1893-z
_version_ 1783416684227330048
author Burgers, L. E.
van der Pol, J. A.
Huizinga, T. W. J.
Allaart, C. F.
van der Helm-van Mil, A. H. M.
author_facet Burgers, L. E.
van der Pol, J. A.
Huizinga, T. W. J.
Allaart, C. F.
van der Helm-van Mil, A. H. M.
author_sort Burgers, L. E.
collection PubMed
description OBJECTIVES: To study the impact of treatment strategy on achieving and sustaining disease-modifying antirheumatic drug (DMARD)-free remission in patients with rheumatoid arthritis (RA). METHODS: Two hundred seventy-nine RA patients (median follow-up 7.8 years) were studied. Of these, 155 patients participated in a disease activity score (DAS) < 1.6 steered trial aimed at DMARD-free remission. Initial treatment comprised methotrexate with high-dose prednisone (60 mg/day) and a possibility to start biologicals after 4 months. In the same period and hospital, 124 patients were treated according to routine care, comprising DAS < 2.4 steered treatment. Percentages of DMARD-free remission (absence of synovitis for ≥ 1 year after DMARD cessation), late flares (recurrence of clinical synovitis ≥ 1 year after DMARD cessation), and DMARD-free sustained remission (DMARD-free remission sustained during complete follow-up) were compared between both treatment strategies. RESULTS: Patients receiving intensive treatment were younger and more often ACPA-positive. On a group level, there was no significant association between intensive treatment and DMARD-free remission (35% vs 29%, corrected hazard ratio (HR) 1.4, 95%CI 0.9–2.2), nor in ACPA-negative RA (49% versus 44%). In ACPA-positive RA intensive treatment resulted in more DMARD-free remission (25% vs 6%, corrected HR 4.9, 95%CI 1.4–17). Intensive treatment was associated with more late flares (20% versus 8%, HR 2.3, 95%CI 0.6–8.3). Subsequently, there was no difference in DMARD-free sustained remission on a group level (28% versus 27%), nor in the ACPA-negative (43% versus 42%) or ACPA-positive stratum (17% versus 6%, corrected HR 3.1, 95%CI 0.9–11). CONCLUSIONS: Intensive treatment did not result in more DMARD-free sustained remission, compared to routine up-to-date care. The data showed a tendency towards an effect of intensive treatment in ACPA-positive RA; this needs further investigation. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13075-019-1893-z) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6505077
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-65050772019-05-10 Does treatment strategy influence the ability to achieve and sustain DMARD-free remission in patients with RA? Results of an observational study comparing an intensified DAS-steered treatment strategy with treat to target in routine care Burgers, L. E. van der Pol, J. A. Huizinga, T. W. J. Allaart, C. F. van der Helm-van Mil, A. H. M. Arthritis Res Ther Research Article OBJECTIVES: To study the impact of treatment strategy on achieving and sustaining disease-modifying antirheumatic drug (DMARD)-free remission in patients with rheumatoid arthritis (RA). METHODS: Two hundred seventy-nine RA patients (median follow-up 7.8 years) were studied. Of these, 155 patients participated in a disease activity score (DAS) < 1.6 steered trial aimed at DMARD-free remission. Initial treatment comprised methotrexate with high-dose prednisone (60 mg/day) and a possibility to start biologicals after 4 months. In the same period and hospital, 124 patients were treated according to routine care, comprising DAS < 2.4 steered treatment. Percentages of DMARD-free remission (absence of synovitis for ≥ 1 year after DMARD cessation), late flares (recurrence of clinical synovitis ≥ 1 year after DMARD cessation), and DMARD-free sustained remission (DMARD-free remission sustained during complete follow-up) were compared between both treatment strategies. RESULTS: Patients receiving intensive treatment were younger and more often ACPA-positive. On a group level, there was no significant association between intensive treatment and DMARD-free remission (35% vs 29%, corrected hazard ratio (HR) 1.4, 95%CI 0.9–2.2), nor in ACPA-negative RA (49% versus 44%). In ACPA-positive RA intensive treatment resulted in more DMARD-free remission (25% vs 6%, corrected HR 4.9, 95%CI 1.4–17). Intensive treatment was associated with more late flares (20% versus 8%, HR 2.3, 95%CI 0.6–8.3). Subsequently, there was no difference in DMARD-free sustained remission on a group level (28% versus 27%), nor in the ACPA-negative (43% versus 42%) or ACPA-positive stratum (17% versus 6%, corrected HR 3.1, 95%CI 0.9–11). CONCLUSIONS: Intensive treatment did not result in more DMARD-free sustained remission, compared to routine up-to-date care. The data showed a tendency towards an effect of intensive treatment in ACPA-positive RA; this needs further investigation. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13075-019-1893-z) contains supplementary material, which is available to authorized users. BioMed Central 2019-05-07 2019 /pmc/articles/PMC6505077/ /pubmed/31064384 http://dx.doi.org/10.1186/s13075-019-1893-z Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Burgers, L. E.
van der Pol, J. A.
Huizinga, T. W. J.
Allaart, C. F.
van der Helm-van Mil, A. H. M.
Does treatment strategy influence the ability to achieve and sustain DMARD-free remission in patients with RA? Results of an observational study comparing an intensified DAS-steered treatment strategy with treat to target in routine care
title Does treatment strategy influence the ability to achieve and sustain DMARD-free remission in patients with RA? Results of an observational study comparing an intensified DAS-steered treatment strategy with treat to target in routine care
title_full Does treatment strategy influence the ability to achieve and sustain DMARD-free remission in patients with RA? Results of an observational study comparing an intensified DAS-steered treatment strategy with treat to target in routine care
title_fullStr Does treatment strategy influence the ability to achieve and sustain DMARD-free remission in patients with RA? Results of an observational study comparing an intensified DAS-steered treatment strategy with treat to target in routine care
title_full_unstemmed Does treatment strategy influence the ability to achieve and sustain DMARD-free remission in patients with RA? Results of an observational study comparing an intensified DAS-steered treatment strategy with treat to target in routine care
title_short Does treatment strategy influence the ability to achieve and sustain DMARD-free remission in patients with RA? Results of an observational study comparing an intensified DAS-steered treatment strategy with treat to target in routine care
title_sort does treatment strategy influence the ability to achieve and sustain dmard-free remission in patients with ra? results of an observational study comparing an intensified das-steered treatment strategy with treat to target in routine care
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6505077/
https://www.ncbi.nlm.nih.gov/pubmed/31064384
http://dx.doi.org/10.1186/s13075-019-1893-z
work_keys_str_mv AT burgersle doestreatmentstrategyinfluencetheabilitytoachieveandsustaindmardfreeremissioninpatientswithraresultsofanobservationalstudycomparinganintensifieddassteeredtreatmentstrategywithtreattotargetinroutinecare
AT vanderpolja doestreatmentstrategyinfluencetheabilitytoachieveandsustaindmardfreeremissioninpatientswithraresultsofanobservationalstudycomparinganintensifieddassteeredtreatmentstrategywithtreattotargetinroutinecare
AT huizingatwj doestreatmentstrategyinfluencetheabilitytoachieveandsustaindmardfreeremissioninpatientswithraresultsofanobservationalstudycomparinganintensifieddassteeredtreatmentstrategywithtreattotargetinroutinecare
AT allaartcf doestreatmentstrategyinfluencetheabilitytoachieveandsustaindmardfreeremissioninpatientswithraresultsofanobservationalstudycomparinganintensifieddassteeredtreatmentstrategywithtreattotargetinroutinecare
AT vanderhelmvanmilahm doestreatmentstrategyinfluencetheabilitytoachieveandsustaindmardfreeremissioninpatientswithraresultsofanobservationalstudycomparinganintensifieddassteeredtreatmentstrategywithtreattotargetinroutinecare